Abstract
Using short peptide fragments of proteins to elicit antibodies able to recognize the protein from which the peptide sequence was derived, is one of the main goals in immunotherapy today. Indeed, peptide-immunotherapy appears as an obliged way to obtain antibodies of predetermined specificity and exempt from the complications associated with whole cells/entire protein vaccines. However, effective peptide-immunotherapy remains an exciting theoretical speculation largely unrealized to date. The major obstacle in designing effective peptide vaccines is our incapacity to scientifically define peptide immunogenicity. This mini-review schematically describes: 1) the available methods to identify epitopic peptides; 2) the sequence redundancy concept as a possible basis for peptide immunogenicity.
Keywords: Peptide-antibody interaction, antigenicity, immunogenicity, peptide features, redundant sequences
Current Drug Discovery Technologies
Title: Peptimmunology: Immunogenic Peptides and Sequence Redundancy
Volume: 2 Issue: 4
Author(s): Darja Kanduc
Affiliation:
Keywords: Peptide-antibody interaction, antigenicity, immunogenicity, peptide features, redundant sequences
Abstract: Using short peptide fragments of proteins to elicit antibodies able to recognize the protein from which the peptide sequence was derived, is one of the main goals in immunotherapy today. Indeed, peptide-immunotherapy appears as an obliged way to obtain antibodies of predetermined specificity and exempt from the complications associated with whole cells/entire protein vaccines. However, effective peptide-immunotherapy remains an exciting theoretical speculation largely unrealized to date. The major obstacle in designing effective peptide vaccines is our incapacity to scientifically define peptide immunogenicity. This mini-review schematically describes: 1) the available methods to identify epitopic peptides; 2) the sequence redundancy concept as a possible basis for peptide immunogenicity.
Export Options
About this article
Cite this article as:
Kanduc Darja, Peptimmunology: Immunogenic Peptides and Sequence Redundancy, Current Drug Discovery Technologies 2005; 2 (4) . https://dx.doi.org/10.2174/157016305775202946
DOI https://dx.doi.org/10.2174/157016305775202946 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Type 1 Diabetes Before and at the Clinical Onset of Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Anti-Infective and Anti-Tumor Agents Based on the Depletion of Immune Suppressive Effects
Current Medicinal Chemistry Metal-Based Antimicrobial Protease Inhibitors
Current Medicinal Chemistry Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties
Current Pharmaceutical Design The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance
Current Molecular Medicine Gold Nanomaterials: From Preparation to Pharmaceutical Design and Application
Current Pharmaceutical Design Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Heterocyclic Analogues as Kinase Inhibitors: A Focus Review
Current Topics in Medicinal Chemistry Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157
Current Medicinal Chemistry Disposition of Flavonoids Impacts their Efficacy and Safety
Current Drug Metabolism Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP
Combinatorial Chemistry & High Throughput Screening Metabolic Activation of Herbal and Dietary Constituents and Its Clinical and Toxicological Implications: An Update
Current Drug Metabolism Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
Current Pharmaceutical Design Hepatocellular Carcinoma: Beyond the Boundaries of Age
Anti-Cancer Agents in Medicinal Chemistry The Role of Culture and Ethnicity in the Adjustment to Gynecological Cancer
Current Women`s Health Reviews Leveraging Cell Cycle Analysis in Anticancer Drug Discovery to Identify Novel Plasmodial Drug Targets
Infectious Disorders - Drug Targets Application of NMR to the Study of Cells and Body Fluids
Current Organic Chemistry